Merck Sharp & Dohme Corp. - Recruiting 18 years or older. - A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI).
MK-7655 250 mg with imipenem/cilastatin; MK-7655 125 mg with imipenem/cilastatin; imipenem/cilastatin 500 mg; Placebo to MK-7655
AstraZeneca - Recruiting 18 years to 90 years. - An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens.
Ceftazidime - Avibactam ( CAZ-AVI); Best Available Therapy; Metronidazole
Swiss Paraplegic Centre Nottwil - Recruiting 18 years to 90 years. - Clinical Value of Homeopathic Assessment and Treatment for Prophylaxis of Recurrent Urinary Tract Infections in Persons With Spinal Cord Injury.
individual homeopathic treatment; standard treatment without homeopathy
AstraZeneca - Recruiting 18 years to 90 years. - A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults.
CAZ-AVI; Doripenem; Either switch to oral therapy: 500 mg of Ciprofloxacin (oral); or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Mashhad University of Medical Sciences - Recruiting 18 years to 55 years. - Comparison of the Effect of Applying Povidone-iodine and Chlorhexidine Solutions for Perinea Washing on Bacteriuria Rate and Type in Patients With Urinary Catheter in Intensive Care Unit.
Innovative Chemical and Environmental Technologies, Inc - Recruiting 18 years or older. - A Randomized Trial for the Safety and Effectiveness of a Novel Antimicrobial-Coated Foley Catheter Attached to an Antimicrobial Anti-Reflux Device for Reduction of Catheter-Associated Urinary Tract Infection.
ICETT TIC Foley Catheter; BARDr LUBRI-SILr IC Foley Catheter